Colinz Laboratories
48.20
+2.20(+4.78%)
Market Cap₹6.08 Cr
PE Ratio11.73
IndustryHealthcare
Company Performance:
1D+4.78%
1M+4.81%
6M+19.54%
1Y-17.51%
5Y+421.65%
View Company Insightsright
More news about Colinz Laboratories
13Dec 25
Colinz Laboratories Files Share Transmission Disclosure Under Insider Trading Rules
Colinz Laboratories has submitted regulatory disclosure under SEBI's Prohibition of Insider Trading Regulations following the transmission of 8,67,750 equity shares from late promoter Dr. Mani L.S. to his nominee Mrs. Vijaya Mani. The transmission increases Mrs. Mani's shareholding from 15.11% to 49.56%, making her the largest individual shareholder while maintaining overall promoter group holdings unchanged.
 no imag found
27Nov 25
Colinz Laboratories Grants Authority for Factory Sale and Appoints New Company Secretary
Colinz Laboratories Ltd announced two major decisions following a board meeting on November 27, 2025. The board authorized Mr. Narayan Kutty Menon, Whole-time Director and CEO, to negotiate the sale of the company's factory premises. This decision follows shareholder approval via postal ballot on November 17, 2025. Additionally, Ms. Falguni Kumawat, with 10 years of experience, has been appointed as the new Company Secretary and Compliance Officer, effective December 1, 2025.
 no imag found
17Nov 25
Colinz Laboratories Shareholders Approve Property Sale and Lease Resolutions
Colinz Laboratories Limited shareholders approved two special resolutions via postal ballot, allowing the company to sell, lease, mortgage, or dispose of its factory in Sinnar, Nashik, and office in Mumbai. The e-voting, conducted from October 15 to November 14, 2025, saw 99.9996% votes in favor, with 61.0979% of total shares participating. This approval grants the company flexibility in managing its property assets, potentially impacting its operational and financial structure.
 no imag found
12Nov 25
Colinz Laboratories Announces Board Changes and Committee Restructuring
Colinz Laboratories, a pharmaceutical company, has made significant changes to its board and committee structure. Following the passing of Dr. Mani L.S., a Non-Executive Director, Mrs. Vijaya Mani has been appointed as an Additional Non-Executive Director, effective November 11, 2025, pending shareholder approval. Mrs. Mani, a BA graduate with experience in Admin and Banking, brings pharmaceutical industry knowledge to the board. The company has also restructured its committees, with Mr. B. B. Dias chairing the Audit, Nomination and Remuneration, and Stakeholders' Relationship Committees, while Mrs. Vijaya Mani chairs the Risk Management Committee.
 no imag found
08Nov 25
Colinz Laboratories Founder Director Dr. Mani L.S. Passes Away; Company to Appoint New Compliance Officer
Colinz Laboratories Limited announced the passing of its Founder Director, Dr. Mani L.S., on November 7, 2025. Dr. Mani also served as Company Secretary and Compliance Officer. Mr. Ganesh Chitte, CFO, has been appointed as Interim Compliance Overseer. The company is taking steps to appoint a new Company Secretary and Compliance Officer. Colinz Laboratories, with ISIN code INE923C01011, has its corporate office in Mumbai.
 no imag found
03Nov 25
Colinz Laboratories Reports Q2 FY2026 Results: Revenue Dips, Profit Rises
Colinz Laboratories Limited, a pharmaceutical formulations manufacturer, announced its Q2 FY2026 results. Revenue decreased to ₹138.80 lakhs from ₹156.61 lakhs in Q1, but net profit increased to ₹14.05 lakhs from ₹11.92 lakhs. Half-year revenue stood at ₹295.41 lakhs with a net profit of ₹25.97 lakhs. The company's total assets reached ₹1,212.62 lakhs with strong liquidity of ₹742.18 lakhs in cash and equivalents. Despite revenue decline, improved profitability suggests effective cost management.
 no imag found
14Oct 25
Colinz Laboratories Seeks Shareholder Approval for Rs 6 Crore Asset Sale
Colinz Laboratories Ltd plans to sell two key assets valued at a minimum of Rs 6.00 crores, subject to shareholder approval via postal ballot. The assets include a pharmaceutical manufacturing factory in Sinnar, Nashik (valued at Rs 3.00 crores) and office premises in Mumbai (valued at Rs 3.00 crores). The sale aims to address high costs of compliance with new WHO norms and infrastructure limitations. The company is considering setting up a new factory in Gujarat or acquiring a ready-made WHO-compliant facility with the sale proceeds. Shareholder voting period is set from October 15 to November 14, 2025.
 no imag found
31Jul 25
Colinz Laboratories Approves Q1 Results, Appoints New Directors
Colinz Laboratories Limited approved unaudited Q1 FY2025-26 results and made significant appointments. Mr. Swapnil Jayeshbhai Madiyar recommended as Non-Executive Director and Mr. N. K. Menon for reappointment as Whole Time Director and CEO. The company scheduled its 39th AGM for September 30, 2025, via video conference. Appointments for Secretarial and Internal Auditors were also made. E-voting for AGM set from September 27 to 29, 2025.
 no imag found
31Jul 25
Colinz Laboratories Approves Q1 Results, Appoints New Directors, and Sets AGM Date
Colinz Laboratories Limited approved unaudited Q1 financial results for the quarter ended June 30, 2025. The Board recommended appointing Mr. Swapnil Jayeshbhai Madiyar as Non-Promoter, Non-Executive Director and reappointing Mr. N. K. Menon as Whole Time Director and CEO. The 39th AGM is scheduled for September 30, 2025, via video conference. The company appointed Secretarial and Internal Auditors for FY 2025-26. E-voting for eligible shareholders will be available from September 27 to 29, 2025.
 no imag found
31Jul 25
Colinz Laboratories Approves Q1 Results, Appoints New Directors
Colinz Laboratories Limited approved unaudited Q1 FY2025-26 results and made significant leadership changes. The Board recommended Mr. Swapnil Jayeshbhai Madiyar as Non-Executive Director and reappointed Mr. N. K. Menon as Whole Time Director and CEO. The 39th AGM is scheduled for September 30, 2025, via video conference. The company also appointed secretarial and internal auditors for FY2025-26.
 no imag found
Colinz Laboratories
48.20
+2.20
(+4.78%)
1 Year Returns:-17.51%
Industry Peers
Sun Pharmaceutical
1,665.20
(-0.20%)
Divis Laboratories
6,286.00
(+0.10%)
Torrent Pharmaceuticals
4,135.70
(-1.32%)
Lupin
2,311.50
(-0.74%)
Dr Reddys Laboratories
1,220.60
(-0.97%)
Cipla
1,232.50
(+0.24%)
Zydus Life Science
928.60
(-0.84%)
Mankind Pharma
2,200.00
(+2.61%)
Aurobindo Pharma
1,391.70
(+1.75%)
Alkem Laboratories
5,696.50
(+0.97%)